Blog
RSS FeedPosted by Michael Wonder on 08 Feb 2022
Pharmacist substitution of PBS medicines without a prescription during shortages (Serious Scarcity Substitution Instrument) - 8 February 2022
8 February 2022 - From 8 February 2022, abatacept syringe (Orencia) and abatacept auto-injector (Orencia ClickJect) can be interchangeably substituted ...
Posted by Michael Wonder on 07 Feb 2022
Review of the National Medicines Policy – consultation on draft National Medicines Policy extended
8 February 2022 - The consultation period on the draft NMP was due to close on Wednesday 16 February 2022. ...
Posted by Michael Wonder on 07 Feb 2022
Mentoring as a potential means to assist consumer representatives contribute effectively to the assessment of health technologies in Australia: a pragmatic review
7 February 2022 - This project was implemented on behalf of the Health Technology Assessment Consumer Consultative Committee to explore training ...
Posted by Michael Wonder on 07 Feb 2022
Analysis of consumer comments into PBAC decision-making (2014–9)
4 February 2022 - Our objective was to analyse and review consumer comments in the PBAC's decision-making process. ...
Posted by Michael Wonder on 07 Feb 2022
DoH publishes revised agenda for next month's PBAC meeting
7 February 2022 - The revised agenda notes three changes. ...
Posted by Michael Wonder on 07 Feb 2022
Medicines Australia calls for new National Medicines Policy to be pushed back until after the federal election
4 February 2022 - Medicines Australia is today calling for the new National Medicines Policy to be pushed back until ...
Posted by Michael Wonder on 03 Feb 2022
Stakeholder consultation forum: post-market review of opiate dependence treatment program medicines
3 February 2022 - A stakeholder consultation forum for the post-market review of opiate dependence treatment program medicines will be ...
Posted by Michael Wonder on 03 Feb 2022
Eligible Australian kids 16+ can now get a booster
3 February 2022 - From today, eligible Australians aged 16 and 17 years old will be able to receive a COVID-19 ...
Posted by Michael Wonder on 02 Feb 2022
Review of the National Medicines Policy – consultation on the draft closes 16 February 2022
2 February 2022 - Since August 2021, the Committee has heard from nearly 200 stakeholders through bilateral interviews and virtual group ...
Posted by Michael Wonder on 01 Feb 2022
'Lifesaving' cystic fibrosis drug Trikafta recommended for inclusion on PBS
1 February 2022 - Thousands of people with cystic fibrosis are one step closer to accessing a 'lifesaving' drug, after ...
Posted by Michael Wonder on 01 Feb 2022
Four million additional Australians eligible for their booster dose
31 January 2022 - Over four million additional Australians are now eligible for their COVID-19 booster dose from today, with the ...
Posted by Michael Wonder on 31 Jan 2022
Schedule of Pharmaceutical Benefits - 1 February 2022 update
1 February 2022 - The February 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Jan 2022
PBS listing to benefit Australians with rare type of non-Hodgkin lymphoma
31 January 2022 - From 1 February, thousands of Australians with a relapsed and/or refractory mantle cell lymphoma, a form of ...
Posted by Michael Wonder on 30 Jan 2022
How are child specific utility instruments used in decision making in Australia? A review of Pharmaceutical Benefits Advisory Committee public summary documents.
28 January 2022 - Measuring and valuing health-related quality of life in children can be challenging but is an important component ...
Posted by Michael Wonder on 28 Jan 2022
Recommendations made by the PBAC – December 2021 intracycle meeting
28 January 2022 - Recommendations made by the PBAC in December 2021 relating to the listing of medicines on the PBS ...